Company: ARWR
Filing Date: 2025-12-11
Form Type: S-3ASR
Source: 0001193125-25-314755
Chunk: 3

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-12-11
Form: S-3ASR
Chunk 3
---
 Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is December 10, 2025

TABLE OF CONTENTS

| ABOUT THIS PROSPECTUS                             |     |  1 |
| SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS |     |  2 |
| ABOUT THE COMPANY                                 |     |  3 |
| RISK FACTORS                                      |     |  4 |
| USE OF PROCEEDS                                   |     |  5 |
| DESCRIPTION OF SECURITIES                         |     |  6 |
| SELLING STOCKHOLDERS                              |     | 15 |
| PLAN OF DISTRIBUTION                              |     | 16 |
| EXPERTS                                           |     | 19 |
| LEGAL MATTERS                                     |     | 19 |
| WHERE YOU CAN FIND MORE INFORMATION               |     | 20 |
| INCORPORATION OF CERTAIN INFORMATION BY REFERENCE |     | 21 |

ABOUT THIS PROSPECTUS

This prospectus is part of an automatic shelf registration statement that we filed with the Securities and Exchange Commission (the
“SEC”), as a “well-known seasoned issuer” as defined in Rule 405 under the Securities Act of 1933, as amended (the “Securities Act”). Under this shelf registration process, we and/or selling stockholders may offer
common stock, preferred stock, debt securities or warrants over time in one or more offerings at prices and on terms to be determined by market conditions at the time of the offering. This prospectus only provides you with a general description of
the securities we and/or selling stockholders may offer. Each time we and/or selling stockholders sell any common stock, preferred stock, debt securities or warrants under this prospectus, we will provide a prospectus supplement that will contain
more specific information about the securities being offered and the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. Each
prospectus supplement and any relating free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents incorporated by reference into this prospectus. If
there is any inconsistency between the information in this prospectus and any accompanying prospectus supplement or related free writing prospectus, you